HCC
MCID: HPT023
MIFTS: 94

Hepatocellular Carcinoma (HCC)

Categories: Genetic diseases, Rare diseases, Liver diseases, Cancer diseases, Endocrine diseases, Gastrointestinal diseases

Aliases & Classifications for Hepatocellular Carcinoma

MalaCards integrated aliases for Hepatocellular Carcinoma:

Name: Hepatocellular Carcinoma 57 38 12 76 59 75 37 29 13 55 6 15
Liver Cancer 57 12 75 6 43 15
Hcc 57 12 59 75
Hepatoma 57 12 75
Hepatocellular Carcinoma, Childhood Type, Somatic 57 6
Adult Primary Hepatocellular Carcinoma 12 73
Primary Malignant Neoplasm of Liver 12 73
Malignant Neoplasm of Liver 12 73
Hepatoblastoma, Somatic 57 13
Cancer, Hepatocellular 57 40
Liver Cell Carcinoma 57 75
Primary Liver Cancer 12 53
Liver Neoplasms 44 73
Hepatic Cancer 12 55
Hepatoblastoma 59 73
Liver Neoplasm 12 15
Lcc 57 75
Malignant Neoplasm of Liver, Not Specified As Primary or Secondary 12
Epithelial Hepatic and Intrahepatic Bile Duct Neoplasm 12
Rare Tumor of Liver and Intrahepatic Biliary Tract 53
Non-Resectable Primary Hepatic Malignant Neoplasm 12
Liver and Intrahepatic Biliary Tract Carcinoma 73
Resectable Malignant Neoplasm of the Liver 12
Resectable Malignant Neoplasm of Liver 12
Malignant Neoplasm of Liver, Primary 12
Hepatocellular Carcinoma, Somatic 57
Malignant Hepato-Biliary Neoplasm 12
Primary Malignant Liver Neoplasm 53
Malignant Hepatobiliary Neoplasm 73
Hepatocellular Cancer, Somatic 57
Primary Tumor of the Liver 53
Liver Cell Carcinoma; Lcc 57
Carcinoma, Hepatocellular 44
Malignant Tumor of Liver 12
Primary Cancer of Liver 53
Primary Liver Carcinoma 53
Hepatocellular Cancer 75
Neoplasm of the Liver 29
Ca Liver - Primary 12
Neoplasm of Liver 12
Hepatic Neoplasm 12
Liver Carcinoma 73
Adult Hepatoma 12

Characteristics:

Orphanet epidemiological data:

59
hepatocellular carcinoma
Inheritance: Not applicable; Prevalence: 1-9/100000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: adult;
hepatoblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe),1-9/1000000 (Europe); Age of onset: Childhood,Infancy,Neonatal; Age of death: early childhood,infantile;

OMIM:

57
Inheritance:
somatic mutation

Miscellaneous:
genetic heterogeneity


HPO:

32
hepatocellular carcinoma:
Inheritance somatic mutation heterogeneous autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare hepatic diseases


Summaries for Hepatocellular Carcinoma

MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. Primary liver cancer starts in the liver. Metastatic liver cancer starts somewhere else and spreads to your liver. Risk factors for primary liver cancer include Having hepatitis B or C Heavy alcohol use Having cirrhosis, or scarring of the liver Having hemochromatosis, an iron storage disease Obesity and diabetes Symptoms can include a lump or pain on the right side of your abdomen and yellowing of the skin. However, you may not have symptoms until the cancer is advanced. This makes it harder to treat. Doctors use tests that examine the liver and the blood to diagnose liver cancer. Treatment options include surgery, radiation, chemotherapy, or liver transplantation. NIH: National Cancer Institute

MalaCards based summary : Hepatocellular Carcinoma, also known as liver cancer, is related to adult hepatocellular carcinoma and childhood hepatocellular carcinoma, and has symptoms including hepatosplenomegaly, icterus and abdominal pain. An important gene associated with Hepatocellular Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Hepatocellular carcinoma and Viral carcinogenesis. The drugs Feridex I.V. and Nexavar have been mentioned in the context of this disorder. Affiliated tissues include liver, t cells and endothelial, and related phenotypes are hypotension and hepatomegaly

OMIM : 57 Hepatocellular carcinoma is the major histologic type of malignant primary liver neoplasm. It is the fifth most common cancer and the third most common cause of death from cancer worldwide. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes. Hepatoblastomas comprise 1 to 2% of all malignant neoplasms of childhood, most often occurring in children under 3 years of age. Hepatoblastomas are thought to be derived from undifferentiated hepatocytes (Taniguchi et al., 2002). (114550)

UniProtKB/Swiss-Prot : 75 Hepatocellular carcinoma: A primary malignant neoplasm of epithelial liver cells. The major risk factors for HCC are chronic hepatitis B virus (HBV) infection, chronic hepatitis C virus (HCV) infection, prolonged dietary aflatoxin exposure, alcoholic cirrhosis, and cirrhosis due to other causes.

Disease Ontology : 12 A liver carcinoma that has material basis in undifferentiated hepatocytes.

Wikipedia : 76 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer in adults, and is the... more...

Related Diseases for Hepatocellular Carcinoma

Diseases in the Hepatocellular Carcinoma family:

Adult Hepatocellular Carcinoma

Diseases related to Hepatocellular Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 503)
# Related Disease Score Top Affiliating Genes
1 adult hepatocellular carcinoma 36.7 AXIN1 CASP8 CTNNB1 PDGFRL PIK3CA TP53
2 childhood hepatocellular carcinoma 36.2 CTNNB1 MET
3 colorectal cancer 35.2 APC AXIN1 CASP8 CTNNB1 HRAS MET
4 breast cancer 34.9 APC CASP8 CTNNB1 HRAS IGF2R MET
5 cholangiocarcinoma 34.5 CTNNB1 HRAS MET MIR21 PIK3CA TERT
6 lung cancer 34.4 CASP8 CTNNB1 HRAS MET MIR146A MIR155
7 prostate cancer 34.1 CASP8 CTNNB1 HRAS MET MIR146A MIR195
8 gastric cancer 33.8 APC CTNNB1 MET MIR122 MIR21 MIR221
9 adenocarcinoma 33.6 APC CTNNB1 HRAS PIK3CA TP53
10 lung cancer susceptibility 3 33.6 APC CASP8 CTNNB1 HRAS MET NRAS
11 melanoma 33.3 MIR122 MIR221 MIR224 MIR34A NRAS TP53
12 glioblastoma 33.3 HRAS MET MIR21 MIR221 MIR34A NRAS
13 esophageal cancer 33.2 CTNNB1 HRAS MIR21 MIR34A PIK3CA TERT
14 gastric adenocarcinoma 33.2 APC CASP8 CTNNB1 HRAS MET NRAS
15 glioma 33.1 MET MIR21 MIR221 MIR34A PIK3CA TP53
16 hepatoblastoma 33.0 APC CTNNB1 TP53
17 cervical cancer 32.9 CASP8 CTNNB1 HRAS MIR21 PIK3CA TERT
18 familial adenomatous polyposis 32.8 APC AXIN1 CTNNB1 TP53
19 adrenocortical carcinoma, hereditary 32.8 CTNNB1 MIR195 NRAS PIK3CA TP53
20 thyroid cancer, nonmedullary, 1 32.4 MIR146A MIR155 MIR21 MIR221 MIR34A
21 pancreas adenocarcinoma 32.4 CTNNB1 HRAS PIK3CA TP53
22 myeloma, multiple 32.2 CASP8 HRAS NRAS TP53
23 diffuse large b-cell lymphoma 32.2 MIR155 MIR21 MIR221 TP53
24 lymphoma, non-hodgkin, familial 32.1 CASP8 NRAS PIK3CA TP53
25 liver angiosarcoma 32.1 HRAS NRAS TP53
26 cystadenocarcinoma 32.1 HRAS PIK3CA TP53
27 dermatomyositis 32.0 MIR21 MIR221 MIR34A
28 colorectal adenocarcinoma 32.0 CTNNB1 HRAS TP53
29 kidney cancer 32.0 MET MIR122 MIR21
30 polymyositis 31.8 MIR155 MIR21
31 familial adenomatous polyposis 1 31.8 APC CTNNB1
32 pancreatic cancer 12.7 CTNNB1 HRAS MET MIR146A MIR155 MIR21
33 ovarian cancer 12.6 CASP8 CTNNB1 MIR146A MIR155 MIR195 MIR21
34 medulloblastoma 12.6 APC AXIN1 CASP8 CTNNB1 MIR34A NRAS
35 leukemia, acute myeloid 12.6 CASP8 HRAS MIR146A MIR155 MIR195 MIR21
36 leukemia, chronic lymphocytic 12.6 CASP8 HRAS MIR146A MIR155 MIR195 MIR21
37 squamous cell carcinoma, head and neck 12.6 CTNNB1 HRAS MIR122 MIR155 MIR195 MIR21
38 thyroid cancer 12.5 APC CTNNB1 HRAS MET NRAS PIK3CA
39 brain cancer 12.4 AXIN1 CASP8 CTNNB1 HRAS NRAS PIK3CA
40 mixed fibrolamellar hepatocellular carcinoma 12.4
41 neuroblastoma 12.3 CASP8 CTNNB1 MIR221 MIR34A NRAS PIK3CA
42 respiratory system cancer 12.3 CTNNB1 HRAS MET PIK3CA TERT TP53
43 adamantinoma of long bones 12.3 APC CASP8 CTNNB1 PIK3CA TERT TP53
44 skin melanoma 12.3 CTNNB1 HRAS NRAS PIK3CA TERT TP53
45 nasopharyngeal carcinoma 12.3 CTNNB1 HRAS NRAS PIK3CA TERT TP53
46 oral squamous cell carcinoma 12.2 MIR122 MIR146A MIR155 MIR21 MIR221 MIR224
47 gastrointestinal system cancer 12.2 CTNNB1 HRAS MET PIK3CA TP53
48 renal cell carcinoma, papillary, 1 12.2 HRAS MET NRAS PIK3CA TP53
49 fibrolamellar carcinoma 12.2
50 bladder urothelial carcinoma 12.2 CTNNB1 HRAS NRAS PIK3CA TP53

Comorbidity relations with Hepatocellular Carcinoma via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Hepatic Encephalopathy Intrahepatic Gall Duct Cancer
Portal Hypertension Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hepatocellular Carcinoma:



Diseases related to Hepatocellular Carcinoma

Symptoms & Phenotypes for Hepatocellular Carcinoma

Symptoms via clinical synopsis from OMIM:

57
Abdomen Liver:
hepatocellular carcinoma
micronodular cirrhosis
subacute progressive viral hepatitis

Laboratory Abnormalities:
often integrated hbv sequences in hepatocellular carcinomas

Neoplasia:
primary liver cancer


Clinical features from OMIM:

114550

Human phenotypes related to Hepatocellular Carcinoma:

59 32 (show all 49)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hypotension 59 32 very rare (1%) Very rare (<4-1%) HP:0002615
2 hepatomegaly 59 32 hallmark (90%) Very frequent (99-80%) HP:0002240
3 type ii diabetes mellitus 59 32 frequent (33%) Frequent (79-30%) HP:0005978
4 portal hypertension 59 32 hallmark (90%) Very frequent (99-80%) HP:0001409
5 fever 59 32 occasional (7.5%) Occasional (29-5%) HP:0001945
6 hypokalemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002900
7 fatigue 59 32 occasional (7.5%) Occasional (29-5%) HP:0012378
8 dyspnea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002094
9 hypoglycemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001943
10 ascites 59 32 occasional (7.5%) Occasional (29-5%) HP:0001541
11 anemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001903
12 abdominal pain 59 32 hallmark (90%) Very frequent (99-80%) HP:0002027
13 neoplasm 59 32 occasional (7.5%) Occasional (29-5%) HP:0002664
14 weight loss 59 32 frequent (33%) Frequent (79-30%) HP:0001824
15 elevated hepatic transaminases 59 32 frequent (33%) Frequent (79-30%) HP:0002910
16 thrombocytopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001873
17 jaundice 59 32 occasional (7.5%) Occasional (29-5%) HP:0000952
18 anorexia 59 32 frequent (33%) Frequent (79-30%) HP:0002039
19 thrombocytosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001894
20 hyponatremia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002902
21 hypercalcemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0003072
22 diarrhea 59 32 occasional (7.5%) Occasional (29-5%) HP:0002014
23 bone pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0002653
24 internal hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0011029
25 esophageal varix 59 32 frequent (33%) Frequent (79-30%) HP:0002040
26 venous insufficiency 59 32 frequent (33%) Frequent (79-30%) HP:0005293
27 liver abscess 59 32 very rare (1%) Very rare (<4-1%) HP:0100523
28 hyperbilirubinemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0002904
29 abdominal distention 59 32 frequent (33%) Frequent (79-30%) HP:0003270
30 polycythemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001901
31 edema of the lower limbs 59 32 occasional (7.5%) Occasional (29-5%) HP:0010741
32 hypoalbuminemia 59 32 hallmark (90%) Very frequent (99-80%) HP:0003073
33 poor appetite 59 32 occasional (7.5%) Occasional (29-5%) HP:0004396
34 abnormality of the rectum 59 32 frequent (33%) Frequent (79-30%) HP:0002034
35 metabolic alkalosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0200114
36 mood changes 59 32 occasional (7.5%) Occasional (29-5%) HP:0001575
37 hepatic encephalopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0002480
38 abnormality of glycoprotein metabolism 59 32 occasional (7.5%) Occasional (29-5%) HP:0004367
39 budd-chiari syndrome 59 32 very rare (1%) Very rare (<4-1%) HP:0002639
40 hepatic necrosis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002605
41 epigastric pain 59 32 frequent (33%) Frequent (79-30%) HP:0410019
42 anasarca 59 32 occasional (7.5%) Occasional (29-5%) HP:0012050
43 hemobilia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100762
44 abnormality of the liver 59 Very frequent (99-80%)
45 hepatocellular carcinoma 32 HP:0001402
46 abnormality of the hepatic vasculature 59 Very frequent (99-80%)
47 constitutional symptom 59 Occasional (29-5%)
48 micronodular cirrhosis 32 HP:0001413
49 subacute progressive viral hepatitis 32 HP:0006572

UMLS symptoms related to Hepatocellular Carcinoma:


hepatosplenomegaly, icterus, abdominal pain, fever, malaise, constipation, diarrhea, dyspepsia, heartburn, nausea and vomiting, gastrointestinal gas

MGI Mouse Phenotypes related to Hepatocellular Carcinoma:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.22 APC CTNNB1 AXIN1 HRAS CASP8 MET
2 endocrine/exocrine gland MP:0005379 10.16 HRAS CASP8 IGF2R CTNNB1 APC MET
3 embryo MP:0005380 10.13 AXIN1 CASP8 IGF2R CTNNB1 APC MET
4 craniofacial MP:0005382 10.11 AXIN1 HRAS IGF2R CTNNB1 APC TP53
5 digestive/alimentary MP:0005381 10.1 AXIN1 HRAS APC CTNNB1 TERT MET
6 neoplasm MP:0002006 10.02 HRAS CASP8 CTNNB1 APC TP53 NRAS
7 limbs/digits/tail MP:0005371 9.98 APC CTNNB1 AXIN1 MET TP53 NRAS
8 liver/biliary system MP:0005370 9.95 APC CTNNB1 CASP8 MET TP53 NRAS
9 normal MP:0002873 9.91 CTNNB1 AXIN1 HRAS APC TERT MET
10 no phenotypic analysis MP:0003012 9.87 APC CTNNB1 HRAS MET TP53 NRAS
11 renal/urinary system MP:0005367 9.76 AXIN1 HRAS CASP8 IGF2R CTNNB1 APC
12 respiratory system MP:0005388 9.56 AXIN1 HRAS CASP8 IGF2R CTNNB1 TERT
13 skeleton MP:0005390 9.28 APC CTNNB1 AXIN1 HRAS TERT TP53

Drugs & Therapeutics for Hepatocellular Carcinoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Feridex I.V. 18 FERUMOXIDES Advanced Magnetics February 1996
2
Nexavar 18 49 SORAFENIB TOSYLATE Bayer/Onyx December 2005

Drugs for Hepatocellular Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 566)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 284461-73-0 216239 406563
2
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 198153-51-4 5360545
3
Ribavirin Approved Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 36791-04-5 37542
4
Entecavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 142217-69-4 153941
5
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
6
Carboplatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 41575-94-4 10339178 498142 38904
7
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
8
Ethiodized oil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 8008-53-5
9
Cefazolin Approved Phase 4 25953-19-9 656510 33255
10
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 525-66-6 4946
11
Telbivudine Approved, Investigational Phase 4,Phase 1,Phase 2 3424-98-4 159269
12
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 61825-94-3 5310940 9887054 43805 6857599
13
Coal tar Approved Phase 4,Phase 3,Phase 2 8007-45-2
14
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7553-56-2 807
15
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142340-99-6 60871
16
Desflurane Approved Phase 4 57041-67-5 42113
17
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
18
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
19
Nadolol Approved Phase 4 42200-33-9 39147
20
Metformin Approved Phase 4,Phase 3,Phase 2 657-24-9 14219 4091
21
Pravastatin Approved Phase 4,Phase 3,Phase 2 81093-37-0 54687
22
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
23
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
24
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
25
Epirubicin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 56420-45-2 41867
26
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2 99210-65-8, 215647-85-1
27
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
28
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
29
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
30
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
31
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 104987-11-3 445643 439492
32
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 169590-42-5 2662
33
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
34
Colchicine Approved Phase 4,Phase 2 64-86-8 6167 2833
35
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
36
Dalteparin Approved Phase 4,Phase 2,Phase 3,Not Applicable 9005-49-6
37
Dipyridamole Approved Phase 4 58-32-2 3108
38
Heparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 9005-49-6 772 46507594
39 Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 9041-08-1
40
Warfarin Approved Phase 4,Not Applicable 81-81-2 6691 54678486
41
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
42
Pregabalin Approved, Illicit, Investigational Phase 4,Not Applicable 148553-50-8 5486971
43
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
44
Thymalfasin Approved, Investigational Phase 4,Phase 2 62304-98-7
45
Ledipasvir Approved Phase 4,Phase 3 1256388-51-8 67505836
46
Sofosbuvir Approved Phase 4,Phase 3,Phase 2,Not Applicable 1190307-88-0 45375808
47
Norepinephrine Approved Phase 4 51-41-2 439260
48
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 2 128794-94-5 5281078
49
Mycophenolic acid Approved Phase 4,Phase 2 24280-93-1 446541
50
chenodeoxycholic acid Approved Phase 4,Phase 3 474-25-9 10133

Interventional clinical trials:

(show top 50) (show all 1793)
# Name Status NCT ID Phase Drugs
1 Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma Unknown status NCT02504983 Phase 4 sorafenib
2 Transarterial Radioembolization Versus Chemoembolization for the Treatment of Hepatocellular Carcinoma Unknown status NCT02729506 Phase 4
3 Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma Unknown status NCT01570166 Phase 4
4 Radiofrequency Ablation Versus Liver Resection for Elderly Patients With Hepatocellular Carcinoma (HCC) Within the Milan Criteria Unknown status NCT01570075 Phase 4
5 A Prospective Control Study of Cidan Capsule Combined With TACE in Hepatocellular Carcinoma Unknown status NCT02253511 Phase 4 Cidan capsule
6 Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) Unknown status NCT01409499 Phase 4 sorafenib
7 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma Unknown status NCT00834860 Phase 4 peginterferon alpha-2a and ribavirin
8 Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00555334 Phase 4 lamivudine or entecavir
9 Radiotherapy as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma Unknown status NCT00557024 Phase 4
10 Radiofrequency Ablation Versus Hepatic Resection for the Treatment of Hepatocellular Carcinomas Smaller Than 2 cm Unknown status NCT01351194 Phase 4
11 TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma Unknown status NCT00556803 Phase 4
12 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis Unknown status NCT01350206 Phase 4
13 Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma Unknown status NCT01833299 Phase 4
14 Efficacy of Antiviral Therapy After Radical Resection for Hepatitis B Virus-Related Hepatocellular Carcinoma Unknown status NCT00768157 Phase 4 antiviral treatment (lamivudine or entecavir)
15 Prophylactic Antibiotics Before RFA for HCC Unknown status NCT02534961 Phase 4 Cefazolin
16 Trial of Ablation of Small Hepatocellular Carcinomas in Patients of Cirrhosis Unknown status NCT01438437 Phase 4
17 Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Unknown status NCT01970748 Phase 4 Propranolol
18 Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy Unknown status NCT01102335 Phase 4 Telbivudine
19 A RCT of Oral S-1 in Combination With Sequential HAIC of Oxaliplatin After TACE in Patients With Advanced HCC Unknown status NCT01997957 Phase 4 S-1
20 Radiofrequency Ablation Combined With Transcatheter Arterial Chemoembolization Versus Radiofrequency Ablation Alone for Recurrent Hepatocellular Carcinoma Unknown status NCT01415063 Phase 4
21 Radiofrequency Ablation With or With Transcatheter Arterial Embolization for Hepatocellular Carcinoma Unknown status NCT00554905 Phase 4
22 Endoscopic Treatment Alone Versus Combined Propranolol and Endoscopic Treatment of Acute Variceal Hemorrhage in Patients With Hepatocellular Carcinoma Unknown status NCT01451658 Phase 4 propranolol
23 Chemoembolization With or Without Antiviral Therapy for Unresectable HBV-related HCC With Low HBV DNA Replication Unknown status NCT01894269 Phase 4 Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.
24 A Clinical Trail of Iodine[131I] Metuximab Injection With CIK Cells for Preventing Hepatocellular Carcinoma Unknown status NCT01758679 Phase 4
25 RFA for Small HCC With No-touch Technique Using Octopus Electrode Unknown status NCT02832882 Phase 4
26 RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode Unknown status NCT02806076 Phase 4
27 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
28 Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection Unknown status NCT00810524 Phase 4 lamivudine;Telbivudine;Enticavir;Adefovir Dipivoxil Tablets
29 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Unknown status NCT02174575 Phase 4 Sevoflurane;Desflurane
30 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
31 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
32 Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
33 Cholestatic Drug-induced Liver Injury Unknown status NCT01141322 Phase 4 Ursodeoxycholic Acid;Placebo
34 Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Unknown status NCT00663182 Phase 4 Entecavir
35 Magnetic Resonance With Gadoxetic Acid for the Diagnosis of Hepatocellular Carcinoma in Patients With Liver Cirrhosis. Evaluation of Its Impact for the Non-invasive Diagnosis Completed NCT01575574 Phase 4 GADOXETIC ACID
36 Drug-eluting Bead in Hepatocellular Carcinoma Completed NCT01332669 Phase 4
37 Resection vs. Best Supportive Care for Hepatocellular Carcinoma (HCC) With Portal Venous Thrombus Completed NCT01600196 Phase 4
38 Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Completed NCT00646100 Phase 4
39 Selective Internal Radiation Therapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Hepatocellular Carcinoma (HCC). Completed NCT01798160 Phase 4
40 Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients Completed NCT01098760 Phase 4 Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment
41 Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma Completed NCT00829465 Phase 4 Licartin
42 Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC Completed NCT00375661 Phase 4 interferon-alfa-2b and ribavirin
43 Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC) Completed NCT01203787 Phase 4 Sorafenib Standard Dosing Regimen;Sorafenib Ramp-Up Regimen
44 Preoperative Transarterial Chemoembolization for Resectable HCC With Portal Venous Invasion Completed NCT01952353 Phase 4
45 Hepatic Xenetix-CT Perfusion Completed NCT01639703 Phase 4 Xenetix-CT perfusion imaging
46 Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma Completed NCT00630084 Phase 4 pegylated interferon alpha 2a and plus ribavirin;pegylated interferon alpha 2a and plus ribavirin
47 Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis Completed NCT03007212 Phase 4
48 The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) Completed NCT00397540 Phase 4
49 Huaier Granule for Prevention of Recurrence and Metastasis of Hepatocarcinoma After Radical Hepatectomy Completed NCT01770431 Phase 4 Huaier Granule
50 A Study With Clevudine Monotherapy or Adefovir and Clevudine Combination in Proportion to Roadmap Concept in Patients With HBV Associated-HCC Completed NCT01263002 Phase 4 clevudine, Adefovir

Search NIH Clinical Center for Hepatocellular Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hepatocellular Carcinoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Hepatocellular Carcinoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 23904171 21498393 22996367 19304471 22555974 15800326 23650429 21325070 24218514 8170938 12242449

Cochrane evidence based reviews: carcinoma, hepatocellular

Genetic Tests for Hepatocellular Carcinoma

Genetic tests related to Hepatocellular Carcinoma:

# Genetic test Affiliating Genes
1 Hepatocellular Carcinoma 29 APC AXIN1 CASP8 CTNNB1 IGF2R MET PDGFRL PIK3CA TP53
2 Neoplasm of the Liver 29

Anatomical Context for Hepatocellular Carcinoma

MalaCards organs/tissues related to Hepatocellular Carcinoma:

41
Liver, T Cells, Endothelial, Testes, Bone, Lung, Colon

Publications for Hepatocellular Carcinoma

Articles related to Hepatocellular Carcinoma:

(show top 50) (show all 13285)
# Title Authors Year
1
The prognostic value of Niemann-Pick C1-like protein 1 and Niemann-Pick disease type C2 in hepatocellular carcinoma. ( 29483961 )
2018
2
CHK2 overexpression and mislocalisation within mitotic structures enhances chromosomal instability and hepatocellular carcinoma progression. ( 28360097 )
2018
3
Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma. ( 29127494 )
2018
4
Rottlerin upregulates DDX3 expression in hepatocellular carcinoma. ( 29203243 )
2018
5
Investigating the risk factors of hepatocellular carcinoma and survival analysis for cirrhosis after transjugular intrahepatic portosystemic shunt in treating portal hypertension. ( 29970660 )
2018
6
<i>Tachypleus tridentatus</i> Lectin Enhances Oncolytic Vaccinia Virus Replication to Suppress In Vivo Hepatocellular Carcinoma Growth. ( 29880736 )
2018
7
Mulberry leaf extract inhibit hepatocellular carcinoma cell proliferation via depressing IL-6 and TNF-I+ derived from adipocyte. ( 29976395 )
2018
8
Hepatocellular carcinoma-associated depletion of the netrin-1 receptor Uncoordinated Phenotype-5A (UNC5A) skews the hepatic unfolded protein response towards prosurvival outcomes. ( 29277614 )
2018
9
Glutamine synthetase mediates sorafenib sensitivity in I^-catenin-active hepatocellular carcinoma cells. ( 29303508 )
2018
10
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma. ( 29034998 )
2018
11
miR-142-3p inhibits aerobic glycolysis and cell proliferation in hepatocellular carcinoma via targeting LDHA. ( 29360449 )
2018
12
Tetrandrine Enhances Radiosensitization in Human Hepatocellular Carcinoma Cell Lines. ( 29979637 )
2018
13
Efficacy of<sup>125</sup>I Versus Non-<sup>125</sup>I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice. ( 29305738 )
2018
14
A human-specific switch of alternatively spliced<i>AFMID</i>isoforms contributes to<i>TP53</i>mutations and tumor recurrence in hepatocellular carcinoma. ( 29449409 )
2018
15
Disseminated interstitial granuloma annulare associated with hepatocellular carcinoma. ( 29774572 )
2018
16
MiR-613 functions as tumor suppressor in hepatocellular carcinoma by targeting YWHAZ. ( 29551505 )
2018
17
Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/I^-catenin pathway. ( 29445127 )
2018
18
The Identification of Core Gene Expression Signature in Hepatocellular Carcinoma. ( 29977454 )
2018
19
Angiomyolipoma of the Liver without a Fat Component, Mimicking a Hepatocellular Carcinoma. ( 29361814 )
2018
20
p.Q511L mutation of HNF1I+ in hepatocellular carcinoma suppresses the transcriptional activity and the anti-tumor effect of HNF1I+. ( 29101032 )
2018
21
Risk of Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis. ( 29942224 )
2018
22
Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. ( 29974040 )
2018
23
EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy. ( 29449645 )
2018
24
Pediatric hepatoblastoma and hepatocellular carcinoma: lessons learned in the last decade. ( 29383417 )
2018
25
Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. ( 29124987 )
2018
26
Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable? ( 29353268 )
2018
27
Dihydroartemisinin induced caspase-dependent apoptosis through inhibiting the specificity protein 1 pathway in hepatocellular carcinoma SK-Hep-1 cells. ( 29128513 )
2018
28
Subacute invasive aspergillosis associated with sorafenib therapy for hepatocellular carcinoma. ( 29370392 )
2018
29
Preoperative computed tomography and serum I+-fetoprotein to predict microvascular invasion in hepatocellular carcinoma. ( 29979435 )
2018
30
Albumin-to-Alkaline Phosphatase Ratio as an Independent Prognostic Factor for Overall Survival of Advanced Hepatocellular Carcinoma Patients without Receiving Standard Anti-Cancer Therapies. ( 29290785 )
2018
31
Correction to: Radioembolization for Hepatocellular Carcinoma Arising in the Setting of a Congenital Extrahepatic Portosystemic Shunt (Abernethy Malformation). ( 29931385 )
2018
32
Downregulation of Nedd4L predicts poor prognosis, promotes tumor growth and inhibits MAPK/ERK signal pathway in hepatocellular carcinoma. ( 29175326 )
2018
33
Autophagy promotes metastasis and glycolysis by upregulating MCT1 expression and Wnt/I^-catenin signaling pathway activation in hepatocellular carcinoma cells. ( 29351758 )
2018
34
Double-Dose Adenovirus-Mediated Adjuvant Gene Therapy Improves Liver Transplantation Outcomes in Patients with Advanced Hepatocellular Carcinoma. ( 29446997 )
2018
35
Outcome of ABO-incompatible adult living-donor liver transplantation for patients with hepatocellular carcinoma. ( 29452208 )
2018
36
Heme oxygenase-1/carbon monoxide axis suppresses transforming growth factor-I^1-induced growth inhibition by increasing ERK1/2-mediated phosphorylation of Smad3 at Thr-179 in human hepatocellular carcinoma cell lines. ( 29524413 )
2018
37
Laparoscopic liver resection of hepatocellular carcinoma located in segments 7 or 8. ( 28730274 )
2018
38
The role of albumin-bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy. ( 29322205 )
2018
39
Comparing Clonality Between Components of Combined Hepatocellular Carcinoma and Cholangiocarcinoma by Targeted Sequencing. ( 29976634 )
2018
40
Hepatic Paragonimiasis Mimicking Hepatocellular Carcinoma. ( 29340921 )
2018
41
Interreader Reliability of LI-RADS Version 2014 Algorithm and Imaging Features for Diagnosis of Hepatocellular Carcinoma: A Large International Multireader Study. ( 29091751 )
2018
42
Integrated analysis of long noncoding RNA expression profiles in lymph node metastasis of hepatocellular carcinoma. ( 29981417 )
2018
43
Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells. ( 29117515 )
2018
44
RACK1 Silencing Induces Cell Apoptosis and Inhibits Cell Proliferation in Hepatocellular Carcinoma MHCC97-H Cells. ( 28396991 )
2018
45
MicroRNA-181a inhibits autophagy by targeting Atg5 in hepatocellular carcinoma. ( 28930552 )
2018
46
Post-operative delayed elevation of ALT correlates with early death in patients with HBV-related hepatocellular carcinoma and Post-hepatectomy Liver Failure. ( 29373299 )
2018
47
Radioembolization for hepatocellular carcinoma: Statistical confirmation of improved survival in responders by landmark analyses. ( 28833344 )
2018
48
Unique Responses of Hepatocellular Carcinoma and Cholangiocarcinoma Cell Lines toward Cantharidin and Norcantharidin. ( 29937938 )
2018
49
Castleman disease in the hilum liver mimicking the lymph node metastasis of hepatocellular carcinoma on 18F-FDG PET/CT: A case report. ( 29561464 )
2018
50
Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. ( 29976149 )
2018